161058-27-1Relevant articles and documents
PIPERAZINYL METHANONE NAAA INHIBITORS
-
Paragraph 0215; 0304, (2017/12/16)
Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.
Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis
Migliore, Marco,Pontis, Silvia,Fuentes de Arriba, Angel Luis,Realini, Natalia,Torrente, Esther,Armirotti, Andrea,Romeo, Elisa,Di Martino, Simona,Russo, Debora,Pizzirani, Daniela,Summa, Maria,Lanfranco, Massimiliano,Ottonello, Giuliana,Busquet, Perrine,Jung, Kwang -Mook,Garcia-Guzman, Miguel,Heim, Roger,Scarpelli, Rita,Piomelli, Daniele
supporting information, p. 11193 - 11197 (2016/10/13)
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation. Their actions are terminated by the intracellular cysteine amidase, N-acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti-inflammatory therapy, the lipid-like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole–piperazine derivatives that inhibit NAAA in a potent and selective manner by a non-covalent mechanism are described. A prototype member of this class (8) displays high oral bioavailability, access to the central nervous system (CNS), and strong activity in a mouse model of multiple sclerosis (MS). This compound exemplifies a second generation of non-covalent NAAA inhibitors that may be useful in the treatment of MS and other chronic CNS disorders.
